Search Results for "340B"

The Drug Pricing Lab takes issue with The New York Times "Fact Check" on the recent Trump Administration proposal to pilot alternative reimbursement for Part B drugs.

As the 340B program expands, it continues to draw national attention.

An alternative payment model is proposed to support a population-level payment paradigm.

Research tells us 9% of hospitals would lose their 340B eligibility under Trump's drug pricing plan. Essentially all are in Medicaid expansion states.

The Centers for Medicare & Medicaid Services (CMS) finalizes OPPS changes for 2018, including ASP -22.5% for drugs obtained through the 340B program.

The Drug Pricing Lab submits a response to CMS-1678-P proposed changes to the Hospital Outpatient Prospective Payment Policy (OPPS).

The Drug Pricing Lab and Commonwealth Fund are partnering with Health Affairs to create a series of educational primers on key topics in U.S. drug pricing.

The 340B program is being converted from one that serves vulnerable patient populations to one that enriches hospitals and their affiliated clinics.

Unintended consequences of the 340B drug discount program alter physician prescribing habits, widen the disparity in hospital profits, and increase list prices of drugs to compensate for revenue losses.